A new peer-reviewed study in the journal Nature says treatment with MDMA reduced symptoms in patients with moderate to severe PTSD. The Phase 3 trial findings mean federal regulators could consider approving the drug for wider use as soon as next year, says the Multidisciplinary Association for Psychedelic Studies (MAPS), which sponsored the research. “Thanks … Continue reading After Latest Clinical Trial, MDMA Therapy For PTSD Is ‘On Track’ For FDA Consideration Next Year